Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Zhu, Ji ^a,b   Xu, Ye ^a,b   Gu, Weilie ^a,b   Peng, Junjie ^a,b   Cai, Gang ^a,b   Cai, Guoxiang ^a,b   Sun, Wenjie ^a,b   Shen, Weiqi ^a,b   Cai, Sanjun ^a,b   Zhang, Zhen ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD44V6 ANTIGEN; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P21; PROTEIN P53;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER; RECTUM RESECTION; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR LOCALIZATION; ABDOMINAL SURGERY; ADENOCARCINOMA; ADJUVANT THERAPY; AGED; EVALUATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECTUM TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 78650048367     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-118     Document Type: Article

References (24)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-40. 10.1056/NEJMoa040694, 15496622.
2. Guillem JG, Diaz-Gonzalez JA, Minsky BD, Valentini V, Jeong SY, Rodriguez-Bigas MA, Coco C, Leon R, Hernandez-Lizoain JL, Aristu JJ, Riedel ER, Nitti D, Wong WD, Pucciarelli S. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008, 26:368-73. 10.1200/JCO.2007.13.5434, 18202411.
3. Kachnic LA, Hong TS, Ryan DP. Rectal cancer at the crossroads: the dilemma of clinically staged T3, N0, M0 disease. J Clin Oncol 2008, 26:350-1. 10.1200/JCO.2007.14.6365, 18202407.
4. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy?. Dis Colon Rectum 1999, 42:167-73. 10.1007/BF02237122, 10211491.
5. Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SH, Wong D, Cohen AM. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999, 3:642-7. 10.1016/S1091-255X(99)80087-0, 10554372.
6. Carlsen E, Schlichting E, Guldvog I, Johnson E, Heald RJ. Effect of the introduction of total mesorectal excision for the treatment of rectal cancer. Br J Surg 1998, 85:526-9. 10.1046/j.1365-2168.1998.00601.x, 9607540.
7. Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, Cai G, Cai S. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J 2008, 14:54-61. 10.1097/PPO.0b013e3181629a67, 18303484.
8. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004, 22:1785-96. 10.1200/JCO.2004.08.173, 15067027.
9. Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol 2002, 20:1744-50. 10.1200/JCO.2002.07.132, 11919230.
10. Lopez-Kostner F, Lavery IC, Hool GR, Rybicki LA, Fazio VW. Total mesorectal excision is not necessary for cancers of the upper rectum. Surgery 1998, 124:612-7. discussion 617-8, 10.1067/msy.1998.91361, 9780979.
11. Leong AF. Selective total mesorectal excision for rectal cancer. Dis Colon Rectum 2000, 43:1237-40. 10.1007/BF02237427, 11005489.
12. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993, 341:457-60. 10.1016/0140-6736(93)90207-W, 8094488.
13. de Haas-Kock DF, Baeten CG, Jager JJ, Langendijk JA, Schouten LJ, Volovics A, Arends JW. Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 1996, 83:781-5. 10.1002/bjs.1800830617, 8696739.
14. Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, van Houwelingen HC, van de Velde CJ. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 1999, 25:368-74. 10.1053/ejso.1999.0659, 10419706.
15. Herrlich P, Pals S, Ponta H. CD44 in colon cancer. Eur J Cancer 1995, 31A:1110-2. 10.1016/0959-8049(95)00252-E, 7577002.
16. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001, 44:523-33. 10.1007/BF02234324, 11330579.
17. Liu YJ, Yan PS, Li J, Jia JF. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol 2005, 11:6601-6.
18. Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H, Furukawa K. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 1996, 14:1122-7.
19. Wouters BG, Giaccia AJ, Denko NC, Brown JM. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 1997, 57:4703-6.
20. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996, 381:713-6. 10.1038/381713a0, 8649519.
21. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999, 50:401-23. 10.1146/annurev.med.50.1.401, 10073286.
22. Fu CG, Tominaga O, Nagawa H, Nita ME, Masaki T, Ishimaru G, Higuchi Y, Tsuruo T, Muto T. Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 1998, 41:68-74. 10.1007/BF02236898, 9510313.
23. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dorken B, Daniel PT. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003, 21:3391-401. 10.1200/JCO.2003.07.077, 12885834.
24. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, Ried T. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005, 23:1826-38. 10.1200/JCO.2005.00.406, 15774776.